CMAJ • July 13, 1999; 161 (1)
© 1999 Canadian Medical Association or its licensors
COMMUNIQUE
Volume 9, Number 3 July 1999
The purpose of this section is to increase awareness of ADRs recently reported to the CADRMP. The following cases have been selected on the basis of their seriousness, or the fact that the reactions do not appear in the product monograph. They are intended to prompt reporting. (The terminology used for expressing reactions is based on the World Health Organization's Adverse Reaction Dictionary using the "preferred term.")
Amlodipine (Norvasc [TM]): hearing loss
Sudden hearing loss with residual effects was reported during amlodipine therapy.